,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ADGRF1,"GPR110, hGPCR36, PGR19",ENSG00000153292,Adhesion G protein-coupled receptor F1,6,46997703-47042363,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA038438,Approved,,,,Renal cancer:1.35e-5 (favourable),Mixed,Tissue enhanced,,esophagus: 14.6;kidney: 17.6;urinary bladder: 18.9,gallbladder: 9.4,Group enriched,9.0,A-431: 27.0;CAPAN-2: 99.3;HaCaT: 22.4;PC-3: 33.9;RPTEC TERT1: 38.6;RT4: 104.1
1,AIM1L,"CRYBG2, FLJ38020",ENSG00000176092,Absent in melanoma 1-like,1,26321859-26360052,Predicted intracellular proteins,Evidence at protein level,"HPA029629, HPA029631",Uncertain,,Approved,Nucleoplasm,"Endometrial cancer:5.11e-6 (unfavourable), Pancreatic cancer:3.53e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 51.2;skin: 21.5,placenta: 13.7,Cell line enhanced,,BEWO: 33.9;CACO-2: 36.7;CAPAN-2: 27.8
2,ANXA8,ANX8,ENSG00000265190,Annexin A8,10,47460162-47484158,Predicted intracellular proteins,Evidence at protein level,"HPA045246, HPA047451",,,Approved,Nucleoplasm,"Pancreatic cancer:2.68e-4 (unfavourable), Head and neck cancer:6.07e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 229.1;skin: 368.9,urinary bladder: 64.2,Cell line enhanced,,HaCaT: 409.1;HBEC3-KT: 486.4;hTCEpi: 269.3
3,ARNTL2,"bHLHe6, BMAL2, CLIF, MOP9, PASD9",ENSG00000029153,Aryl hydrocarbon receptor nuclear translocator like 2,12,27332854-27425289,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA059074, HPA065355",Uncertain,,Enhanced,Nucleus<br>Nucleoli,"Pancreatic cancer:5.29e-6 (unfavourable), Renal cancer:1.56e-5 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 31.2,tonsil: 20.2,Cell line enhanced,,U-2197: 148.2
4,ATG9B,"APG9L2, FLJ14885, NOS3AS, SONE",ENSG00000181652,Autophagy related 9B,7,151012209-151024499,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,esophagus: 9.2;placenta: 5.8;skin: 13.5,testis: 3.8,Cell line enhanced,,BEWO: 12.5;CAPAN-2: 3.7
5,ATP12A,"#945, 2, ATP1AL1, HK",ENSG00000075673,ATPase H+/K+ transporting non-gastric alpha2 subunit,13,24680411-24712493,"Enzymes, Plasma proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA039526,Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 12.7;placenta: 8.2;tonsil: 14.1,skin: 7.1,Not detected,,
6,BARX2,,ENSG00000043039,BARX homeobox 2,11,129375940-129452279,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB033311, HPA068414",Enhanced,,Supported,Nucleoplasm<br>Cytosol,Urothelial cancer:3.06e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 103.8;salivary gland: 60.3,fallopian tube: 28.0,Cell line enriched,5.0,HDLM-2: 158.6
7,C15orf62,LOC643338,ENSG00000188277,Chromosome 15 open reading frame 62,15,40770080-40772449,Predicted intracellular proteins,Evidence at protein level,HPA044636,Approved,,,,,Mixed,Tissue enhanced,,esophagus: 14.9;skin: 12.6,tonsil: 4.6,Cell line enhanced,,RPTEC TERT1: 13.6
8,C1orf116,"FLJ36507, MGC2742, MGC4309, SARG",ENSG00000182795,Chromosome 1 open reading frame 116,1,207018521-207032756,Predicted intracellular proteins,Evidence at protein level,"HPA011888, HPA011889",Enhanced,,Supported,Plasma membrane<br>Cytosol,Renal cancer:1.01e-5 (favourable),Mixed,Tissue enhanced,,esophagus: 112.4;lung: 109.2;prostate: 82.0,stomach: 54.9,Group enriched,5.0,A-431: 50.3;CAPAN-2: 87.3;HaCaT: 108.7;HBEC3-KT: 85.0;hTCEpi: 44.4;hTERT-HME1: 26.3;RPTEC TERT1: 42.8
9,C1QTNF3,"2310005P21Rik, Corcs, Cors, Cors-26, CTRP3",ENSG00000082196,C1q and tumor necrosis factor related protein 3,5,34019448-34043832,"Plasma proteins, Predicted secreted proteins",Evidence at protein level,"HPA064996, HPA066011",Uncertain,,Approved,Golgi apparatus,Renal cancer:6.29e-4 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 38.8,smooth muscle: 33.0,Cell line enriched,195.0,U-266/84: 563.8
10,C2orf54,FLJ22671,ENSG00000172478,Chromosome 2 open reading frame 54,2,240886048-240896889,Predicted intracellular proteins,Evidence at protein level,HPA052722,,,Approved,Nucleoplasm<br>Golgi apparatus,Endometrial cancer:2.77e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 112.1;skin: 51.5,tonsil: 25.5,Group enriched,7.0,CACO-2: 49.6;HaCaT: 39.3;SK-BR-3: 116.4
11,C3orf67,"FLJ42117, FLJ42930",ENSG00000163689,Chromosome 3 open reading frame 67,3,58717365-59050084,Predicted intracellular proteins,Evidence at protein level,HPA069696,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,esophagus: 13.2;testis: 47.0,fallopian tube: 6.3,Mixed,,
12,C6orf132,bA7K24.2,ENSG00000188112,Chromosome 6 open reading frame 132,6,42101118-42142619,Predicted intracellular proteins,Evidence at protein level,HPA044588,Enhanced,,Approved,Golgi apparatus<br>Cytosol,Pancreatic cancer:4.90e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 80.8,skin: 49.9,Cell line enhanced,,A-431: 56.9;CACO-2: 48.3;CAPAN-2: 42.1
13,CALML3,CLP,ENSG00000178363,Calmodulin like 3,10,5524009-5526771,"Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins",Evidence at protein level,"CAB010070, HPA044999",Approved,,,,,Group enriched,Tissue enhanced,,esophagus: 165.7;skin: 42.6,tonsil: 22.4,Group enriched,6.0,A-431: 12.2;hTCEpi: 3.8;RPMI-8226: 2.6
14,CAPNS2,"MGC12536, MGC14804",ENSG00000256812,Calpain small subunit 2,16,55566672-55567687,Predicted intracellular proteins,Evidence at protein level,"HPA059749, HPA076768",Enhanced,,Approved,Cytosol,,Group enriched,Tissue enhanced,,esophagus: 59.9;skin: 109.3,urinary bladder: 30.3,Cell line enriched,8.0,hTCEpi: 158.7
15,CCDC190,"C1orf110, MGC48998",ENSG00000185860,Coiled-coil domain containing 190,1,162824458-162868815,Predicted intracellular proteins,Evidence at transcript level,"HPA028579, HPA028584, HPA028592",Uncertain,,Approved,Vesicles,,Mixed,Tissue enhanced,,esophagus: 3.7;lung: 2.8,fallopian tube: 0.8,Cell line enhanced,,hTEC/SVTERT24-B: 3.9;HUVEC TERT2: 4.0;LHCN-M2: 6.0;TIME: 13.6;U-2197: 8.2
16,CDA,CDD,ENSG00000158825,Cytidine deaminase,1,20588948-20618908,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA064202,Enhanced,,Approved,Nucleoplasm,"Pancreatic cancer:8.56e-5 (unfavourable), Cervical cancer:5.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 104.6;esophagus: 56.7,liver: 33.3,Cell line enhanced,,A-431: 142.3;CAPAN-2: 92.8;HeLa: 100.6;SiHa: 200.2
17,CHAC1,MGC4504,ENSG00000128965,ChaC glutathione specific gamma-glutamylcyclotransferase 1,15,40952962-40956519,Predicted intracellular proteins,Evidence at protein level,"HPA042708, HPA043505",Approved,,,,Renal cancer:2.23e-7 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 25.5,pancreas: 14.5,Cell line enhanced,,BJ hTERT+: 88.7;HHSteC: 67.5;hTCEpi: 94.1;SK-MEL-30: 73.8
18,CLIC3,,ENSG00000169583,Chloride intracellular channel 3,9,136994635-136996803,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,HPA005963,Enhanced,,Supported,Nuclear bodies,"Renal cancer:1.12e-4 (unfavourable), Urothelial cancer:7.74e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 86.8;thyroid gland: 85.7,skin: 43.5,Cell line enhanced,,BEWO: 234.7;MCF7: 88.6;T-47d: 100.2;TIME: 70.2
19,CYP4F22,FLJ39501,ENSG00000171954,Cytochrome P450 family 4 subfamily F member 22,19,15508493-15552317,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA058960,Uncertain,,,,,Group enriched,Tissue enhanced,,esophagus: 14.0;skin: 34.3,seminal vesicle: 9.1,Cell line enhanced,,MCF7: 1.3
20,CYSRT1,"C9orf169, MGC59937",ENSG00000197191,Cysteine rich tail 1,9,137224635-137226311,Predicted intracellular proteins,Evidence at protein level,"HPA021883, HPA021886",Approved,,Approved,Nuclear speckles<br>Vesicles<br>Midbody,,Expressed in all,Tissue enhanced,,esophagus: 45.6;skin: 12.2,tonsil: 6.3,Cell line enhanced,,A-431: 11.7;CAPAN-2: 14.5;HaCaT: 16.3;MCF7: 20.0
21,DAPL1,,ENSG00000163331,Death associated protein like 1,2,158795317-158862781,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046937, HPA058635",Enhanced,,Approved,Nucleoplasm<br>Nuclear bodies<br>Microtubules,Cervical cancer:8.43e-4 (favourable),Group enriched,Tissue enhanced,,epididymis: 238.2;esophagus: 243.7;skin: 219.0,fallopian tube: 128.4,Group enriched,5.0,HaCaT: 3.5;hTCEpi: 16.6;SCLC-21H: 6.9;U-87 MG: 8.2
22,DENND2C,"dJ1156J9.1, DKFZp686G0351, DKFZp779P1149, FLJ37099, RP5-1156J9.1",ENSG00000175984,DENN domain containing 2C,1,114582848-114670422,Predicted intracellular proteins,Evidence at protein level,HPA054955,Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,esophagus: 19.5;skeletal muscle: 14.3;skin: 14.8,testis: 10.0,Cell line enhanced,,U-2197: 10.9;U-266/70: 19.3
23,DKK4,,ENSG00000104371,Dickkopf WNT signaling pathway inhibitor 4,8,42374068-42377232,Predicted secreted proteins,Evidence at protein level,HPA052916,Approved,,,,,Tissue enriched,Tissue enhanced,,duodenum: 2.4;esophagus: 5.4;testis: 2.7,urinary bladder: 1.4,Cell line enriched,9.0,Hep G2: 1.4
24,DSC2,"CDHF2, DSC3",ENSG00000134755,Desmocollin 2,18,31058840-31102415,"Disease related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,"HPA011911, HPA012615",Enhanced,,,,"Urothelial cancer:3.01e-4 (unfavourable), Lung cancer:5.80e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 186.7,parathyroid gland: 62.0,Cell line enhanced,,BEWO: 36.6;CAPAN-2: 44.0;HaCaT: 63.9;hTCEpi: 55.4;SK-BR-3: 33.9
25,DUOXA1,"FLJ32334, mol, NIP, NUMBIP",ENSG00000140254,Dual oxidase maturation factor 1,15,45117367-45129938,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA041578,Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 122.2;skin: 107.9;thyroid gland: 112.0,epididymis: 60.3,Cell line enriched,9.0,HaCaT: 92.0
26,EDN2,ET2,ENSG00000127129,Endothelin 2,1,41478775-41484673,Predicted secreted proteins,Evidence at protein level,HPA028459,Uncertain,,Approved,Cytosol,"Endometrial cancer:2.85e-4 (unfavourable), Pancreatic cancer:5.81e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 10.6;small intestine: 18.1,epididymis: 5.5,Cell line enhanced,,CAPAN-2: 12.3;EFO-21: 32.7;SCLC-21H: 19.7;SK-BR-3: 31.2;U-2 OS: 16.7
27,EPHA2,ECK,ENSG00000142627,EPH receptor A2,1,16124337-16156087,"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins",Evidence at protein level,CAB010464,,,Supported,Nuclear speckles<br>Golgi apparatus<br>Plasma membrane<br>Cell Junctions,,Expressed in all,Tissue enhanced,,esophagus: 86.8,gallbladder: 44.5,Cell line enhanced,,PC-3: 211.2;WM-115: 253.0
28,ESPL1,"ESP1, KIAA0165, SEPA",ENSG00000135476,"Extra spindle pole bodies like 1, separase",12,53268299-53293643,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB012185,Uncertain,,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 11.4;testis: 10.6,lymph node: 4.8,Mixed,,
29,EVPLL,,ENSG00000214860,Envoplakin like,17,18377662-18389647,Predicted intracellular proteins,Evidence at transcript level,HPA045728,Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,,Not detected,Tissue enhanced,,esophagus: 1.7;skin: 3.0;testis: 1.5,lung: 0.8,Cell line enhanced,,HeLa: 1.2;hTCEpi: 4.7;RT4: 1.8;SiHa: 1.3;T-47d: 1.9
30,FAM25A,bA96C23.5,ENSG00000188100,Family with sequence similarity 25 member A,10,87020306-87024730,Predicted intracellular proteins,Evidence at transcript level,HPA044808,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 315.5;skin: 125.9,tonsil: 54.6,Group enriched,6.0,A-431: 22.6;SK-BR-3: 55.0
31,FAM46B,MGC16491,ENSG00000158246,Family with sequence similarity 46 member B,1,27005020-27012836,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 59.9;skin: 39.4,seminal vesicle: 22.1,Cell line enhanced,,hTCEpi: 45.0;NTERA-2: 32.9
32,FAM83D,"C20orf129, CHICA, dJ616B8.3",ENSG00000101447,Family with sequence similarity 83 member D,20,38926312-38953106,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:1.81e-14 (unfavourable), Liver cancer:5.44e-6 (unfavourable), Pancreatic cancer:4.73e-5 (unfavourable), Endometrial cancer:1.49e-4 (unfavourable), Lung cancer:9.69e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 76.1;smooth muscle: 131.9,prostate: 21.8,Expressed in all,,
33,FMO2,,ENSG00000094963,Flavin containing monooxygenase 2,1,171185208-171211230,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA028261,Approved,,,,,Mixed,Tissue enhanced,,adipose tissue: 98.3;esophagus: 102.9;lung: 158.2,breast: 55.8,Group enriched,48.0,ASC diff: 27.9;ASC TERT1: 12.9;HSkMC: 35.2
34,FOXN1,"FKHL20, RONU, WHN",ENSG00000109101,Forkhead box N1,17,28506243-28538896,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,"Head and neck cancer:5.00e-4 (favourable), Cervical cancer:6.43e-4 (favourable)",Tissue enhanced,Tissue enhanced,,esophagus: 7.2;skin: 35.2,tonsil: 5.1,Cell line enriched,8.0,HaCaT: 10.3
35,FUT3,"CD174, LE",ENSG00000171124,Fucosyltransferase 3 (Lewis blood group),19,5842888-5851474,"Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046966,Supported,,,,"Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,colon: 68.0;esophagus: 83.0;small intestine: 63.1,rectum: 49.4,Group enriched,5.0,A-431: 40.5;RH-30: 14.4
36,FUT6,"FCT3A, FLJ40754, FT1A, FucT-VI",ENSG00000156413,Fucosyltransferase 6,19,5830610-5839731,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA043707, HPA046966",Approved,,Supported,Golgi apparatus,"Renal cancer:3.17e-8 (favourable), Head and neck cancer:2.12e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 49.8;kidney: 34.5,small intestine: 30.6,Group enriched,5.0,Hep G2: 7.2;RPMI-8226: 2.7
37,FZD10,CD350,ENSG00000111432,Frizzled class receptor 10,12,130162459-130165740,"CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA014484, HPA014485",Uncertain,,Supported,Nucleoplasm,Endometrial cancer:5.05e-7 (favourable),Mixed,Tissue enhanced,,"cervix, uterine: 9.4;esophagus: 8.8",skin: 5.6,Cell line enhanced,,AF22: 5.4;BEWO: 6.1;hTCEpi: 2.6;RT4: 2.5
38,GJB3,"CX31, DFNA2, EKV",ENSG00000188910,Gap junction protein beta 3,1,34781189-34786369,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA074472,,,Supported,Vesicles<br>Cell Junctions,"Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 33.6;skin: 77.3,tonsil: 11.6,Cell line enhanced,,A-431: 76.8;CAPAN-2: 106.8;HaCaT: 87.5;HBEC3-KT: 60.8;hTCEpi: 98.5
39,GNA15,GNA16,ENSG00000060558,G protein subunit alpha 15,19,3136193-3163769,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA043113,Approved,,,,"Renal cancer:4.26e-6 (unfavourable), Breast cancer:7.57e-5 (favourable), Endometrial cancer:2.01e-4 (favourable)",Expressed in all,Tissue enhanced,,bone marrow: 48.7;esophagus: 61.3,skin: 25.9,Cell line enhanced,,HMC-1: 142.1;MOLT-4: 137.5;REH: 115.4
40,GPR87,GPR95,ENSG00000138271,G protein-coupled receptor 87,3,151294086-151316952,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA066313,,,Approved,Nucleoplasm<br>Lipid droplets<br>Mitochondria,Pancreatic cancer:4.62e-6 (unfavourable),Group enriched,Tissue enhanced,,esophagus: 29.3;skin: 29.8,placenta: 12.0,Cell line enhanced,,A-431: 87.7;HaCaT: 68.9;HBEC3-KT: 74.5;hTCEpi: 98.3;hTERT-HME1: 43.6
41,GRHL1,"LBP-32, MGR, TFCP2L2",ENSG00000134317,Grainyhead like transcription factor 1,2,9951693-10002277,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA005798, HPA006420",Enhanced,,Enhanced,Nucleus<br>Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,esophagus: 111.4;skin: 106.8,parathyroid gland: 50.3,Cell line enhanced,,BEWO: 205.8;SK-BR-3: 84.4
42,GRPEL2,"DKFZp451C205, FLJ23713, Mt-GrpE#2",ENSG00000164284,"GrpE like 2, mitochondrial",5,149345430-149354583,Predicted intracellular proteins,Evidence at protein level,"HPA018173, HPA023211",Uncertain,,Enhanced,Mitochondria,"Liver cancer:6.16e-8 (unfavourable), Colorectal cancer:3.87e-5 (favourable), Endometrial cancer:2.21e-4 (unfavourable), Renal cancer:4.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 30.4,thyroid gland: 9.7,Expressed in all,,
43,GSDMC,MLZE,ENSG00000147697,Gasdermin C,8,129748196-129786888,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA023670, HPA024767, HPA026317",Supported,,Enhanced,Mitochondria,,Group enriched,Tissue enhanced,,esophagus: 20.0;skin: 44.3;spleen: 21.6,tonsil: 6.5,Cell line enhanced,,A-431: 13.0;HaCaT: 3.1;hTCEpi: 4.5;HUVEC TERT2: 5.2;TIME: 4.3
44,HIST1H2BF,"H2B/g, H2BFG",ENSG00000277224,Histone cluster 1 H2B family member f,6,26199520-26200715,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,esophagus: 3.5;prostate: 2.6,breast: 2.2,Cell line enhanced,,U-266/70: 18.9;U-266/84: 13.1
45,IL12A,"CLMF, IL-12A, NFSK, NKSF1, p35",ENSG00000168811,Interleukin 12A,3,159988750-159996019,"Cancer-related genes, Plasma proteins, Predicted membrane proteins",Evidence at protein level,HPA001886,Uncertain,,,,,Mixed,Tissue enhanced,,esophagus: 4.0,fallopian tube: 3.2,Cell line enhanced,,HDLM-2: 11.1;SK-BR-3: 12.8
46,IL18,"IGIF, IL-18, IL-1g, IL1F4",ENSG00000150782,Interleukin 18,11,112143251-112164117,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA003980, CAB007772",Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,Colorectal cancer:2.78e-4 (favourable),Expressed in all,Tissue enhanced,,esophagus: 133.0;skin: 171.5,lymph node: 71.9,Cell line enhanced,,CAPAN-2: 155.6;HaCaT: 143.7;hTCEpi: 132.7;U-2 OS: 214.0
47,IL1A,"IL-1A, IL1, IL1-ALPHA, IL1F1",ENSG00000115008,Interleukin 1 alpha,2,112773915-112784590,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,,,,,,"Lung cancer:1.54e-4 (unfavourable), Stomach cancer:4.03e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 12.8;testis: 18.6,tonsil: 7.4,Cell line enhanced,,HBEC3-KT: 302.4;hTCEpi: 147.6;hTERT-HME1: 205.8
48,IL1RN,"ICIL-1RA, IL-1RN, IL1F3, IL1RA, IRAP, MGC10430",ENSG00000136689,Interleukin 1 receptor antagonist,2,113107214-113134016,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA001482, CAB009633",Enhanced,,,,"Renal cancer:2.66e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable), Testis cancer:8.23e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 1243.9,tonsil: 290.5,Cell line enhanced,,A-431: 51.8;HaCaT: 100.6;RT4: 89.4
49,IL36B,"FIL1, FILI-(ETA), IL-1F8, IL-1H2, IL1-ETA, IL1F8, IL1H2, MGC126880, MGC126882",ENSG00000136696,"Interleukin 36, beta",2,113022091-113052867,Predicted intracellular proteins,Evidence at transcript level,HPA035664,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 2.2;skin: 7.3;tonsil: 3.4,breast: 1.2,Cell line enriched,21.0,U-87 MG: 71.9
50,KLK10,"NES1, PRSSL1",ENSG00000129451,Kallikrein related peptidase 10,19,51012739-51020175,"Cancer-related genes, Enzymes, Predicted secreted proteins",Evidence at protein level,HPA017195,,,Uncertain,Plasma membrane<br>Cytosol,"Pancreatic cancer:6.46e-5 (unfavourable), Breast cancer:8.32e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 138.2;skin: 52.7,tonsil: 45.8,Group enriched,5.0,CAPAN-2: 200.9;HaCaT: 307.2
51,KLK11,"PRSS20, TLSP",ENSG00000167757,Kallikrein related peptidase 11,19,51022216-51028039,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB026340,Approved,,,,"Endometrial cancer:3.78e-4 (favourable), Pancreatic cancer:4.17e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 225.7;skin: 214.5,prostate: 104.9,Cell line enhanced,,CAPAN-2: 5.6;EFO-21: 12.3;HaCaT: 36.6
52,KLK12,KLK-L5,ENSG00000186474,Kallikrein related peptidase 12,19,51029092-51035230,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB025473,Uncertain,,,,Thyroid cancer:8.01e-4 (favourable),Tissue enhanced,Tissue enhanced,,esophagus: 32.4,tonsil: 8.1,Not detected,,
53,KRT24,"FLJ20261, MGC138169, MGC138173",ENSG00000167916,Keratin 24,17,40697991-40703750,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA022978,Uncertain,,Approved,Intermediate filaments<br>Cytosol,,Tissue enhanced,Tissue enhanced,,epididymis: 20.3;esophagus: 28.4;tonsil: 67.0,placenta: 10.6,Cell line enriched,11.0,SK-BR-3: 5.3
54,LAD1,,ENSG00000159166,Ladinin 1,1,201373244-201399915,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA007256, HPA028732",Enhanced,,Enhanced,Actin filaments,Lung cancer:6.73e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 291.7;skin: 236.6,small intestine: 93.9,Cell line enhanced,,A-431: 173.4;CAPAN-2: 150.1;HaCaT: 219.8;MCF7: 165.3;RT4: 146.2;SK-BR-3: 220.4
55,LGALS7B,GAL7,ENSG00000178934,Galectin 7B,19,38789211-38791749,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001549, CAB025100",Supported,,,,Endometrial cancer:1.59e-4 (unfavourable),Group enriched,Tissue enhanced,,breast: 10.4;esophagus: 19.3,skeletal muscle: 3.8,Cell line enriched,21.0,HaCaT: 3.7
56,LYNX1,,ENSG00000284505,Ly6/neurotoxin 1,8,142764334-142778224,"Predicted secreted proteins, Transporters",Evidence at protein level,,,,,,,,Tissue enhanced,,esophagus: 5.8,skin: 4.0,Not detected,,
57,LYPD2,"LYPDC2, RGTR430, UNQ430",ENSG00000197353,LY6/PLAUR domain containing 2,8,142750150-142752534,Predicted secreted proteins,Evidence at protein level,HPA028599,Uncertain,,,,"Cervical cancer:2.00e-4 (favourable), Head and neck cancer:2.63e-4 (favourable)",Group enriched,Tissue enhanced,,esophagus: 99.1;tonsil: 24.0,stomach: 20.9,Group enriched,20.0,EFO-21: 9.5;HaCaT: 2.5
58,MALL,BENE,ENSG00000144063,"Mal, T-cell differentiation protein like",2,110083870-110116566,Predicted membrane proteins,Evidence at protein level,HPA051410,Uncertain,,,,Pancreatic cancer:1.23e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 222.2;parathyroid gland: 321.0,small intestine: 182.4,Cell line enhanced,,A-431: 176.6;A549: 174.8;CAPAN-2: 233.6;fHDF/TERT166: 228.9;HaCaT: 183.5
59,MPZL2,"EVA, EVA1",ENSG00000149573,Myelin protein zero like 2,11,118253403-118264536,Predicted membrane proteins,Evidence at protein level,HPA060740,Approved,,Approved,Cell Junctions,"Pancreatic cancer:1.14e-4 (unfavourable), Thyroid cancer:1.62e-4 (favourable)",Expressed in all,Tissue enhanced,,esophagus: 209.1,urinary bladder: 118.1,Cell line enhanced,,CAPAN-2: 107.3;EFO-21: 123.8;HaCaT: 149.0;RT4: 257.4;TIME: 288.5
60,MXD1,"bHLHc58, MAD, MAD1",ENSG00000059728,MAX dimerization protein 1,2,69897688-69942945,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA001599,Enhanced,,Uncertain,Nucleoplasm<br>Mitochondria<br>Cytosol,"Endometrial cancer:8.14e-6 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 113.8;esophagus: 101.9,appendix: 56.3,Mixed,,
61,NDUFA4L2,"FLJ26118, NUOMS",ENSG00000185633,"NDUFA4, mitochondrial complex associated like 2",12,57234903-57240715,Predicted membrane proteins,Evidence at protein level,HPA055323,,,Approved,Mitochondria,Renal cancer:1.37e-5 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 152.3;skin: 191.7,placenta: 104.2,Cell line enriched,8.0,AN3-CA: 123.9
62,NECTIN1,"CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRL1, PVRR1, SK-12",ENSG00000110400,Nectin cell adhesion molecule 1,11,119623408-119729084,"CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB016135, HPA026846",Approved,,,,,Expressed in all,Tissue enhanced,,esophagus: 108.6;skin: 161.7,cerebral cortex: 50.3,Cell line enhanced,,HaCaT: 203.5
63,NECTIN4,"LNIR, nectin-4, PRR4, PVRL4",ENSG00000143217,Nectin cell adhesion molecule 4,1,161070995-161089599,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA010775,Enhanced,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,esophagus: 45.9;skin: 79.5,"breast,placenta: 17.1",Cell line enhanced,,BEWO: 53.8;HaCaT: 32.5;SK-BR-3: 35.3;T-47d: 28.8
64,NIPAL1,"DKFZp686A06115, NPAL1",ENSG00000163293,NIPA like domain containing 1,4,47914142-48040173,Predicted membrane proteins,Evidence at transcript level,HPA036765,Uncertain,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,esophagus: 24.0;skin: 30.8,rectum: 14.6,Cell line enhanced,,A-431: 11.6;HaCaT: 13.6;RT4: 14.3
65,NKX6-1,"Nkx6.1, NKX6A",ENSG00000163623,NK6 homeobox 1,4,84491987-84498450,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA036774, CAB070169",Supported,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,esophagus: 6.9;thyroid gland: 2.9,testis: 1.4,Cell line enhanced,,AF22: 4.0;HAP1: 6.0;HEK93: 4.7;HMC-1: 3.4;U-2197: 5.9
66,OVOL1,HOVO1,ENSG00000172818,Ovo like transcriptional repressor 1,11,65787022-65797219,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003984,Uncertain,,Approved,Nucleus,"Renal cancer:1.00e-13 (favourable), Endometrial cancer:1.87e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 37.3;skin: 33.4;testis: 35.3,urinary bladder: 15.5,Cell line enhanced,,A-431: 16.3;BEWO: 49.5;HaCaT: 27.3;RT4: 24.5;SK-BR-3: 17.8
67,P2RY2,P2U,ENSG00000175591,Purinergic receptor P2Y2,11,73218298-73236352,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,CAB022642,Uncertain,,Uncertain,Cytosol,Pancreatic cancer:2.19e-5 (unfavourable),Mixed,Tissue enhanced,,esophagus: 18.9,skeletal muscle: 14.9,Cell line enhanced,,HaCaT: 31.0;HL-60: 27.2;THP-1: 53.1
68,PKP3,,ENSG00000184363,Plakophilin 3,11,392614-404908,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB012993, HPA062937",Enhanced,,Enhanced,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Lung cancer:2.89e-5 (unfavourable), Renal cancer:1.08e-4 (unfavourable), Pancreatic cancer:3.93e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 98.2;skin: 148.2,duodenum: 31.4,Cell line enhanced,,A-431: 131.6;HaCaT: 174.9;SK-BR-3: 111.1
69,PLA2G2C,,ENSG00000187980,Phospholipase A2 group IIC,1,20161253-20177424,"Predicted secreted proteins, RAS pathway related proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,esophagus: 1.2,testis: 0.6,Cell line enhanced,,HL-60: 1.2;U-698: 1.2;U-937: 1.3
70,PLA2G3,GIII-SPLA2,ENSG00000100078,Phospholipase A2 group III,22,31134809-31140607,"Enzymes, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,HPA021016,Uncertain,,,,Head and neck cancer:4.47e-4 (favourable),Mixed,Tissue enhanced,,esophagus: 4.4;lung: 3.6;skin: 10.2,parathyroid gland: 1.5,Group enriched,6.0,AF22: 14.3;AN3-CA: 13.6;NTERA-2: 7.5;SCLC-21H: 13.2
71,PRDM1,"BLIMP1, PRDI-BF1",ENSG00000057657,PR/SET domain 1,6,106086320-106109939,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030033,Approved,,Approved,Nucleus<br>Nucleoli,Renal cancer:9.81e-5 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 61.0,endometrium: 30.1,Cell line enhanced,,Karpas-707: 158.5;U-266/70: 62.6;U-266/84: 39.9
72,PRSS22,"BSSP-4, hBSSP-4, SP001LA",ENSG00000005001,"Protease, serine 22",16,2852727-2858170,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA049161,Approved,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,esophagus: 7.7;stomach: 11.1,salivary gland: 3.1,Cell line enhanced,,CAPAN-2: 67.3;SK-BR-3: 14.6;T-47d: 16.5
73,PTK6,BRK,ENSG00000101213,Protein tyrosine kinase 6,20,63528001-63537370,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB032952, HPA036070, HPA036071",Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Plasma membrane<br>Cytosol,"Renal cancer:1.26e-9 (unfavourable), Pancreatic cancer:1.96e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 61.0;skin: 60.4,duodenum: 29.2,Cell line enhanced,,A-431: 19.4;CAPAN-2: 36.5;HaCaT: 30.0;hTCEpi: 32.5;RT4: 21.3;T-47d: 23.7
74,RAB25,CATX-8,ENSG00000132698,"RAB25, member RAS oncogene family",1,156061160-156070514,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA010872, CAB033645",Enhanced,,Uncertain,Cell Junctions<br>Cytosol,Renal cancer:1.38e-6 (favourable),Mixed,Tissue enhanced,,esophagus: 297.5,skin: 169.0,Cell line enhanced,,BEWO: 114.9;CAPAN-2: 103.6;MCF7: 128.3;RT4: 119.8;SK-BR-3: 179.2;T-47d: 210.8
75,RAB40A,"Rar-2, RAR2A",ENSG00000172476,"RAB40A, member RAS oncogene family",X,103499130-103519489,"Cancer-related genes, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,epididymis: 9.8;esophagus: 7.8,"prostate,testis: 5.9",Cell line enhanced,,AF22: 3.3;NTERA-2: 3.7
76,RAET1E,"bA350J20.7, LETAL, ULBP4",ENSG00000164520,Retinoic acid early transcript 1E,6,149883375-149898102,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054022,,,Approved,Focal adhesion sites<br>Cytosol,,Tissue enhanced,Tissue enhanced,,esophagus: 70.8;skin: 29.0,tonsil: 10.3,Cell line enhanced,,HBEC3-KT: 15.9;HeLa: 20.3;hTCEpi: 15.6;SiHa: 11.2;U-87 MG: 9.0
77,RAET1G,ULBP5,ENSG00000203722,Retinoic acid early transcript 1G,6,149916878-149923121,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA062673,,,Approved,Vesicles,Lung cancer:5.35e-4 (unfavourable),Mixed,Tissue enhanced,,adrenal gland: 8.2;esophagus: 9.5,skin: 3.4,Cell line enhanced,,HeLa: 21.4;hTCEpi: 18.1;SiHa: 13.3;U-87 MG: 9.8
78,RHOV,"ARHV, Chp, WRCH2",ENSG00000104140,Ras homolog family member V,15,40872214-40874289,Predicted intracellular proteins,Evidence at protein level,HPA053343,Enhanced,,,,"Lung cancer:2.33e-4 (unfavourable), Pancreatic cancer:4.19e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 71.5;skin: 72.6,tonsil: 20.2,Cell line enhanced,,HaCaT: 66.2;SK-BR-3: 237.1
79,RIPK4,"ANKK2, ANKRD3, DIK, PKK, RIP4",ENSG00000183421,Receptor interacting serine/threonine kinase 4,21,41739369-41767106,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA030942,Enhanced,,,,"Ovarian cancer:6.22e-5 (unfavourable), Pancreatic cancer:3.48e-4 (unfavourable), Renal cancer:6.52e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 31.5,small intestine: 15.0,Cell line enhanced,,CAPAN-2: 27.8;HaCaT: 41.4
80,RNASE7,RAE1,ENSG00000165799,Ribonuclease A family member 7,14,21042226-21044234,Predicted secreted proteins,Evidence at protein level,"HPA005690, CAB062560, CAB068225",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 72.0;skin: 29.2;tonsil: 19.6,gallbladder: 11.1,Cell line enhanced,,HBEC3-KT: 17.9;hTCEpi: 7.6;hTERT-HME1: 40.4
81,RNF223,,ENSG00000237330,Ring finger protein 223,1,1070966-1074307,Predicted membrane proteins,Evidence at transcript level,,,,,,"Endometrial cancer:8.08e-5 (favourable), Pancreatic cancer:6.53e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 5.3;stomach: 3.6,skin: 2.0,Cell line enhanced,,A-431: 13.3;CAPAN-2: 9.8;HaCaT: 6.2;MCF7: 18.6;SK-BR-3: 12.0;T-47d: 9.8
82,RNF225,,ENSG00000269855,Ring finger protein 225,19,58396090-58397079,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,esophagus: 2.0;skin: 1.7,prostate: 0.6,Not detected,,
83,S100A14,"BCMP84, S100A15",ENSG00000189334,S100 calcium binding protein A14,1,153614255-153616986,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA027613,Enhanced,,Supported,Nuclear bodies<br>Plasma membrane<br>Cell Junctions<br>Cytosol,,Mixed,Tissue enhanced,,esophagus: 2205.9,skin: 591.6,Group enriched,9.0,A-431: 692.6;HaCaT: 944.8;HBEC3-KT: 1089.8;hTCEpi: 1601.4;SK-BR-3: 1180.8
84,S100A16,"DT1P1A7, MGC17528, S100F",ENSG00000188643,S100 calcium binding protein A16,1,153606886-153613145,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA045841,Enhanced,,Enhanced,Plasma membrane<br>Cytosol,"Lung cancer:3.14e-5 (unfavourable), Renal cancer:3.91e-5 (unfavourable), Pancreatic cancer:2.04e-4 (unfavourable), Liver cancer:3.18e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 1489.4,skin: 394.6,Mixed,,
85,S100A2,"CAN19, S100L",ENSG00000196754,S100 calcium binding protein A2,1,153561108-153567890,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB002600, CAB047340, HPA062451",Enhanced,,Supported,Nucleus<br>Nucleoli<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.04e-4 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 1481.8,tonsil: 368.4,Cell line enhanced,,HBEC3-KT: 15305.5;RT4: 6706.3
86,SAMD9,"C7orf5, FLJ20073, KIAA2004",ENSG00000205413,Sterile alpha motif domain containing 9,7,93099513-93118023,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA021318, HPA021319",Approved,,Enhanced,Vesicles<br>Cytosol,"Renal cancer:8.40e-7 (unfavourable), Pancreatic cancer:8.31e-5 (unfavourable), Lung cancer:2.93e-4 (unfavourable), Endometrial cancer:3.14e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 43.2,spleen: 24.2,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 64.9
87,SCEL,"FLJ21667, MGC22531",ENSG00000136155,Sciellin,13,77535674-77645263,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039737, HPA040154",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane<br>Cytosol,"Urothelial cancer:1.73e-5 (unfavourable), Pancreatic cancer:1.24e-4 (unfavourable), Endometrial cancer:4.07e-4 (unfavourable), Renal cancer:6.87e-4 (favourable)",Mixed,Tissue enhanced,,esophagus: 476.6;skin: 397.0,lung: 98.9,Cell line enhanced,,CAPAN-2: 28.9;HaCaT: 54.8;HBEC3-KT: 21.3;RPTEC TERT1: 89.6
88,SDC1,"CD138, SDC, SYND1, syndecan",ENSG00000115884,Syndecan 1,2,20200797-20225433,"Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters",Evidence at protein level,"CAB002424, HPA006185",Approved,,Supported,Focal adhesion sites,"Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 250.7;skin: 287.9,liver: 144.7,Cell line enhanced,,U-266/84: 739.8
89,SDR9C7,"RDHS, SDR-O",ENSG00000170426,Short chain dehydrogenase/reductase family 9C member 7,12,56923154-56934405,Predicted intracellular proteins,Evidence at protein level,HPA039059,,,Approved,Nucleoli<br>Cytosol,,Group enriched,Tissue enhanced,,esophagus: 10.7;skin: 46.1,tonsil: 6.8,Not detected,,
90,SIM2,"bHLHe15, MGC119447, SIM",ENSG00000159263,Single-minded family bHLH transcription factor 2,21,36699133-36749917,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA029295,Approved,,Supported,Nucleoplasm<br>Nuclear bodies,"Endometrial cancer:2.10e-4 (unfavourable), Urothelial cancer:2.88e-4 (favourable)",Tissue enhanced,Tissue enhanced,,esophagus: 22.8;kidney: 13.0;prostate: 10.3,stomach: 5.1,Cell line enhanced,,PC-3: 40.7;RPTEC TERT1: 41.3;RT4: 26.9
91,SLC10A6,SOAT,ENSG00000145283,Solute carrier family 10 member 6,4,86823468-86849263,Predicted membrane proteins,Evidence at protein level,HPA016662,Enhanced,,,,,Group enriched,Tissue enhanced,,esophagus: 11.0;skin: 17.3,adipose tissue: 6.2,Cell line enhanced,,BJ: 1.4;BJ hTERT+: 1.0;HaCaT: 1.1
92,SPNS2,,ENSG00000183018,Sphingolipid transporter 2,17,4498838-4539035,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA068717,Uncertain,,,,,Expressed in all,Tissue enhanced,,esophagus: 46.4,kidney: 30.0,Group enriched,6.0,BEWO: 29.2;RPTEC TERT1: 120.6;SK-BR-3: 55.8
93,SULT2B1,HSST2,ENSG00000088002,Sulfotransferase family 2B member 1,19,48552075-48599425,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"CAB033013, HPA041724, HPA043539",Approved,,Supported,Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,esophagus: 152.2;skin: 152.4,"cervix, uterine: 45.8",Cell line enhanced,,CAPAN-2: 59.3;MCF7: 32.5;T-47d: 31.4
94,SUSD4,FLJ10052,ENSG00000143502,Sushi domain containing 4,1,223220819-223364202,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA058296,Uncertain,,Approved,Vesicles,Endometrial cancer:4.28e-4 (unfavourable),Mixed,Tissue enhanced,,esophagus: 42.4,cerebral cortex: 38.5,Cell line enriched,5.0,SCLC-21H: 46.1
95,TACSTD2,"EGP-1, GA733-1, M1S1, TROP2",ENSG00000184292,Tumor-associated calcium signal transducer 2,1,58575423-58577773,"Disease related genes, Predicted membrane proteins",Evidence at protein level,"HPA043104, HPA055067, CAB072852",Enhanced,,Supported,Nucleoli<br>Vesicles<br>Plasma membrane,Renal cancer:3.99e-4 (favourable),Mixed,Tissue enhanced,,esophagus: 313.8,skin: 209.6,Cell line enhanced,,A-431: 502.8;CAPAN-2: 665.4;HaCaT: 672.0
96,TMEM154,FLJ32028,ENSG00000170006,Transmembrane protein 154,4,152618632-152680165,Predicted membrane proteins,Evidence at protein level,"HPA019184, HPA055411",Uncertain,,Approved,Nucleoplasm<br>Nuclear membrane,,Mixed,Tissue enhanced,,esophagus: 64.3;skin: 69.5,tonsil: 24.1,Cell line enhanced,,HMC-1: 62.0
97,TP53AIP1,p53AIP1,ENSG00000120471,Tumor protein p53 regulated apoptosis inducing protein 1,11,128934731-128943399,Predicted intracellular proteins,Evidence at transcript level,"HPA044300, HPA048797",Approved,,,,,Tissue enhanced,Tissue enhanced,,esophagus: 6.3;skin: 22.2,fallopian tube: 4.1,Not detected,,
98,TP63,"EEC3, KET, NBP, OFC8, p51, p53CP, p63, p73H, p73L, SHFM4, TP53CP, TP53L, TP73L",ENSG00000073282,Tumor protein p63,3,189631416-189897279,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB000083, HPA006288, HPA007010",Enhanced,,Enhanced,Nucleoplasm<br>Golgi apparatus<br>Cytosol,Breast cancer:1.07e-4 (favourable),Group enriched,Tissue enhanced,,esophagus: 60.9;skin: 164.1,urinary bladder: 28.8,Group enriched,5.0,HaCaT: 77.1;HBEC3-KT: 119.9;hTCEpi: 89.8;hTERT-HME1: 90.5;RT4: 147.6
99,TPRG1,"FAM79B, FLJ41238, FLJ43694",ENSG00000188001,Tumor protein p63 regulated 1,3,188947214-189325304,Predicted intracellular proteins,Evidence at protein level,"HPA044751, HPA060187",Uncertain,,Supported,Nucleoplasm,Breast cancer:5.43e-4 (favourable),Tissue enhanced,Tissue enhanced,,esophagus: 49.1,breast: 28.4,Cell line enhanced,,HDLM-2: 8.9;Karpas-707: 3.3;T-47d: 3.9;U-266/70: 3.5
100,TTC22,FLJ20619,ENSG00000006555,Tetratricopeptide repeat domain 22,1,54779712-54801267,Predicted intracellular proteins,Evidence at protein level,HPA035072,Uncertain,,,,"Breast cancer:2.06e-4 (favourable), Liver cancer:7.73e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 40.6,skin: 22.7,Cell line enhanced,,A-431: 7.9;CAPAN-2: 9.5;HaCaT: 11.0;hTCEpi: 5.0;RPMI-8226: 5.6
101,TTC9,"KIAA0227, TTC9A",ENSG00000133985,Tetratricopeptide repeat domain 9,14,70641787-70675360,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:2.10e-8 (favourable), Endometrial cancer:1.82e-5 (favourable)",Expressed in all,Tissue enhanced,,esophagus: 44.6,fallopian tube: 15.9,Cell line enhanced,,A-431: 15.5;RH-30: 20.2;SK-BR-3: 26.6
102,UPK1A,TSPAN21,ENSG00000105668,Uroplakin 1A,19,35666516-35678483,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA049879,Enhanced,,,,,Tissue enriched,Tissue enhanced,,esophagus: 26.9;urinary bladder: 108.7,skin: 15.6,Cell line enriched,9.0,RT4: 31.3
103,UPP1,"UDRPASE, UP, UPASE, UPP",ENSG00000183696,Uridine phosphorylase 1,7,48088628-48108733,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA054040, HPA055394",Enhanced,,Enhanced,Nucleoplasm,"Cervical cancer:1.02e-4 (unfavourable), Lung cancer:1.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,esophagus: 35.1,appendix: 17.8,Cell line enhanced,,hTERT-HME1: 369.7;WM-115: 110.3
104,USH1G,"ANKS4A, FLJ33924, Sans",ENSG00000182040,USH1 protein network component sans,17,74916084-74923256,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA024360,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,epididymis: 2.3;esophagus: 2.6;skin: 1.8,testis: 1.4,Cell line enhanced,,HaCaT: 1.6;hTCEpi: 1.2;K-562: 1.2;MCF7: 1.5;U-2 OS: 1.0
105,VSIG10L,,ENSG00000186806,V-set and immunoglobulin domain containing 10 like,19,51331536-51342124,Predicted membrane proteins,Evidence at protein level,"HPA060453, HPA066745",Uncertain,,Enhanced,Nucleus,Liver cancer:8.75e-4 (unfavourable),Expressed in all,Tissue enhanced,,esophagus: 31.4;salivary gland: 9.2,skin: 5.9,Group enriched,6.0,Hep G2: 3.2;T-47d: 7.9
106,ZNF185,SCELL,ENSG00000147394,Zinc finger protein 185 (LIM domain),X,152914442-152973480,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000400, HPA016438",Enhanced,,Supported,Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol,"Pancreatic cancer:3.30e-5 (unfavourable), Lung cancer:1.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,epididymis: 400.1;esophagus: 278.4;seminal vesicle: 202.3,"cervix, uterine: 105.3",Cell line enhanced,,A-431: 108.1;EFO-21: 131.6;TIME: 192.3
107,ZNF750,"FLJ13841, Zfp750",ENSG00000141579,Zinc finger protein 750,17,82829435-82840578,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA021573, HPA023012",Enhanced,,,,,Mixed,Tissue enhanced,,esophagus: 60.5;skin: 54.4,salivary gland: 13.0,Cell line enhanced,,BEWO: 16.4;hTCEpi: 4.5;MCF7: 3.6;SK-BR-3: 9.5
